The genetic basis of variability in drug responses

Nature Reviews Drug Discovery

Volumn 1, Issue 1, 2002, Pages 37-44

  Roden, Dan M ^a   George Jr , Alfred L ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CELL NUCLEUS RECEPTOR; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; KETOCONAZOLE; LIPOXYGENASE INHIBITOR; MEPHENYTOIN; MERCAPTOPURINE; OMEPRAZOLE; PHENYTOIN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TACRINE; TIMOLOL; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN; ZILEUTON;

ALKAPTONURIA; ALLELE; ALZHEIMER DISEASE; ANGIONEUROTIC EDEMA; BONE MARROW APLASIA; CHILDHOOD LEUKEMIA; CONGESTIVE HEART FAILURE; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSFORMATION; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENE MUTATION; GENETIC ALGORITHM; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; INBORN ERROR OF METABOLISM; MOLECULAR CLONING; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PUBLIC HEALTH; QT INTERVAL; REVIEW; RHABDOMYOLYSIS; ANIMAL; GENETIC POLYMORPHISM; GENOMICS; PHARMACOKINETICS;

ANIMALS; GENOMICS; HUMANS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 0036043220     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd705     Document Type: Review

References (80)

1. Kennedy, D. L., Johnson, J. M. & Nightingale, S. L. Monitoring of adverse drug events in hospitals. J. Am. Med. Assoc. 266, 2878 (1991).
2. Classen, D. C., Pestotnik, S. L., Evans, R. S., Lloyd, J. F. & Burke, J. P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. J. Am. Med. Assoc. 277, 301-306 (1997).
3. Dormann, H. et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 22, 161-168 (2000).
4. Brewer, T. & Colditz, G. A. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. J. Am. Med. Assoc. 281, 824-829 (1999).
5. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J. Am. Med. Assoc. 286, 2270-2279 (2001).
6. Motulsky, A. G., Harper, P. S., Bobrow, M. & Scriver, C. in Pharmacogenetics 1st edn (ed. Weber, W. W.) 1-20 (Oxford Univ. Press, New York, 1997).
7. Beutler, E., Dern, R. J. & Alving, A. S. The hemolytic effect of primaquine. VI. An in vitro test for sensitivity of erythrocytes to primaquine. J. Lab. Clin. Med. 45, 40-50 (1955).
8. Price-Evans, D. A., Manley, F. A. & McKusick, V. A. Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485-491 (1960).
9. Bönicke, R. & Lisboa, B. P. Uber die Erbbedingtheit der intraindividuellen Konstantz der Isoniazidausscheidung beim Menshen (Untersuchen an eineiggen und zweieiggen Zwilligen). Naturwissenschafften 44, 314 (1957).
10. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
11. Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).
12. Meyer, U. A. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
13. Woosley, R. L. et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med. 298, 1157-1159 (1978).
14. Grant, D. M., Blum, M. & Meyer, U. A. Polymorphisms of N-acetyltransferase genes. Xenobiotica 22, 1073-1081 (1992).
15. Mahgoub, A., Idle, R. J., Dring, L. G., Lancaster, R. & Smith, R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586 (1977).
16. Eichelbaum, M., Spannbrucker, N., Steincke, B. & Dengler, H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16, 183-187 (1979).
17. Caraco, Y., Sheller, J. & Wood, A. J. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J. Pharmacol. Exp. Ther. 290, 413-422 (1999).
18. Brosen, K., Zeugin, T. & Meyer, U. A. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49, 609-617 (1991).
19. Lee, J. T. et al. The role of genetically determined polymorphic drug metabolism in the β-blockade produced by propafenone. N. Engl. J. Med. 322, 1764-1768 (1990).
20. Lennard, M. S. et al. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307, 1558-1560 (1982).
21. Meyer, U. A. & Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
22. Aithal, G. P., Day, C. P., Kesteven, P. J. & Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet 353, 717-719 (1999).
23. Furuta, T. et al, Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129, 1027-1030 (1998).
24. Weinshilboum, R. Methyltransferase pharmacogenetics. Pharmacol. Ther. 43, 77-90 (1989).
25. Ando, Y. et al. Polymorphisms of UDP-glucuronosyltransferase gene and innotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
26. Glatt, H. et al. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res. 482, 27-40 (2001).
27. Forbat, A., Lond, M. B., Lehmann, H. & Silk, E. Prolonged apnea following injection of succinylcholine. Lancet 2, 1067-1068 (1953).
28. Whittaker, M. Genetic aspects of succinylcholine sensitivity. Anesthesiology 32, 143-150 (1970).
29. Vandel, S. et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 25, 202-207 (1992).
30. Woosley, R. L., Chen, Y., Freiman, J. P. & Gillis, R. A. Mechanism of the cardiotoxic actions of terfenadine. J. Am. Med. Assoc. 269, 1532-1536 (1993).
31. Fromm, M. F., Kim, R. B., Stein, C. M., Wilkinson, G. R. & Roden, D. M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99, 552-557 (1999).
32. Kim, R. B. et al. P-glycoprotein transporter limits oral absorption and brain entry of HIV protease inhibitors. J. Clin. Invest. 101, 289-294 (1998).
33. Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000).
34. Kim, R. B. et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
35. Schinkel, A. H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
36. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic, CYP3A5 expression. Nature Genet. 27, 383-391 (2001).
37. Lehmann, J. M. et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023 (1998).
38. Smirlis, D., Muangmoonchai, R., Edwards, M., Phillips, I. R. & Shephard, E. A. Orphan receptor promiscuity in the induction of cytochromes p450 by xenobiotics. J. Biol. Chem. 276, 12822-12826 (2001).
39. Synold, T. W., Dussault, I. & Forman, B. M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 7, 584-590 (2001).
40. Xie, W. et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 14, 3014-3023 (2000).
41. Xie, W. et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406, 435-439 (2000).
42. Poirier, J. et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl Acad. Sci. USA 92, 12260-12264 (1995).
43. Sesti, F. et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl Acad. Sci. USA 97, 10613-10618 (2000).
44. Drazen. J. M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168-170 (1999).
45. Donger, C. et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 96, 2778-2781 (1997).
46. Napolitano, C. et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. 11, 691-696 (2000).
47. Yang, P. et al. Frequency of ion channel mutations and polymorphisms in a large population of patients with drug-associated Long QT Syndrome. Pacing Clin. Electrophys. 24, 579 (2001).
48. KS potassium channels. Circulation 100, 1-495 (1999).
49. Rigat, B. et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346 (1990).
50. Ueda, S., Meredith, P. A., Morton, J. J., Connell, J. M. & Elliott, H. L. ACE(I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 98, 2148-2153 (1998).
51. McNamara, D. M. et al. Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 106, 1644-1648 (2001).
52. Vesell, E. S. & Page, J. G. Genetic control of drug levels in man: antipyrine. Science 161, 72-73 (1968).
53. Hughes, T. R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
54. Sachidanandam, R. et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
55. Stephens, J. C. et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 293, 489-493 (2001).
56. Judson, R. & Stephens, J. C. Notes from the SNP vs haplotype front. Pharmacogenomics 2, 7-10 (2001).
57. Otterness, D. M., Szumlanski, C. L., Wood, T. C. & Weinshilboum, R. M. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J. Clin. Invest. 101, 1036-1044 (1998).
58. McLeod, H. L., Krynetski, E. Y., Relling, M. V. & Evans, W. E. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14, 567-572 (2000).
59. Rothstein, M. A. & Epps, P. G. Ethical and legal implications of pharmacogenomics. Nature Rev. Genet. 2, 228-231 (2001).
60. Robertson, J. A. Consent and privacy in pharmacogenetic testing. Nature Genet. 28, 207-209 (2001).
61. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
62. Pfeffer, M. A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327, 669-677 (1992).
63. Brown, N. J., Ray, W. A., Snowden, M. & Griffin, M. R. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther. 60, 8-13 (1996).
64. Brown, N. J., Snowden, M. & Griffin, M. R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. J. Am. Med. Assoc. 278, 232-233 (1997).
65. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
66. Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
67. Ucar, M., Mjorndal, T. & Dahlqvist, R. HMG-CoA reductase inhibitors and myotoxicity Drug Saf. 22, 441-457 (2000).
68. Kleyn, P. W. & Vesell, E. S. Genetic variation as a guide to drug development. Science 281, 1820-1821 (1998).
69. Mamiya, K. et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39, 1317-1323 (1998).
70. Sullivan-Klose, T. H. et al. The role ofthe CYP2C9 Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996).
71. Wedlund, P. J., Aslanian, W. S., McAllister, C. B., Wilkinson, G. R. & Branch, R. A. Mephenytoin hydroxylation deficiency in caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36, 773-780 (1984).
72. Dahl, M.-L., Johansson, I., Bertilsson, F., Ingelman-Sundberg, M. & Sjoeqvist, F. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274, 516-520 (1995).
73. Edeki, T. I., He, H. & Wood, A. J. Pharmacogenetic, explanation for excessive β-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. J. Am. Med. Assoc. 274, 1611-1613 (1995).
74. Zhou, H. H. & Wood, A. J. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin. Pharmacol. Ther. 57, 518-524 (1995).
75. Idle, J. R., Maingoub, A., Lancaster, R. & Smith, R. L. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci. 22, 979-984 (1978).
76. Ellard, G. A., Mitchison, D. A., Girling, D. J., Nunn, A. J. & Fox, W. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. Am. Rev. Respir. Dis. 118, 628-629 (1978).
77. Stolk, J. N. et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 41, 1858-1866 (1998).
78. Israel, E. et al. The effect of polymorphisms of the β(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 162, 75-80 (2000).
79. Lutucuta, S., Ballantyne, C. M., Elghannam, H., Gotto, A. M., Jr & Marian, A. J. Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ. Res. 88, 969-973 (2001).
80. Kuivenhoven, J. A. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338, 86-93 (1998).